| Description | Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells. Theralizumab has antitumor activity and is used for the treatment of B-cell chronic lymphocytic leukemia and rheumatoid arthritis. |
| Synonyms | TGN1412, TAB-08, TABO8 |
| molecular weight | N/A |
| CAS | 906068-56-2 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Dmitry Tyrsin, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. Jul-Aug 2016;34(4 Suppl 98):45-8. 2. Thomas Hünig. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. FEBS J. 2016 Sep;283(18):3325-34. |